Madrigal Pharmaceuticals to Participate in Key Investor Events
In an exciting development for investors and stakeholders alike, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced participation in important upcoming investor conferences. This opportunity aims to showcase the company's innovative approaches in liver disease treatment and to connect with the investment community.
Details of the Upcoming Conferences
Madrigal Pharmaceuticals will engage in a series of fireside chats, offering insights into their latest research and therapeutic advancements. Here’s what to expect:
Jefferies Global Healthcare Conference
The first stop is the Jefferies Global Healthcare Conference in London. Scheduled for Thursday, this event will take place at 8:30 A.M. GMT. Attendees can look forward to a live web broadcast of the presentation, which aims to cover Madrigal’s advancements in treating metabolic dysfunction-associated steatohepatitis (MASH).
8th Annual Evercore Healthcare Conference
Following the Jefferies event, Madrigal will present at the 8th Annual Evercore Healthcare Conference on Tuesday at 4:15 P.M. ET. This session will also be available via a live webcast, presenting investors with key insights into the company's strategic direction and product developments.
Piper Sandler 37th Annual Healthcare Conference
Lastly, on Wednesday at 1:30 P.M. ET, the company will showcase its initiatives at the Piper Sandler 37th Annual Healthcare Conference. This platform will provide another opportunity for Madrigal to communicate its vision and the impact of its lead candidate, Rezdiffra, a medication targeting serious liver diseases.
About Madrigal Pharmaceuticals and Its Focus
Madrigal Pharmaceuticals is at the forefront of biopharmaceutical innovation, focusing on therapies for MASH, a liver disease with significant unmet medical needs. The company’s flagship product, Rezdiffra (resmetirom), is noteworthy for being the first medication approved by both the FDA and the European Commission for treating MASH with moderate to advanced fibrosis. It has a pivotal role in addressing the challenges posed by this condition, targeting the core issues associated with liver disease.
Rezdiffra is a once-daily, oral medication that functions as a liver-directed THR-? agonist, representing a major leap forward in MASH treatment protocols. Presently, Madrigal is conducting a Phase 3 outcomes trial assessing Rezdiffra's efficacy for patients suffering from compensated MASH cirrhosis (F4c).
Connecting with Investors
The fireside chats during these conferences are more than mere presentations; they represent an authentic dialogue. Investors will have the chance to engage with Madrigal’s leadership and ask pressing questions regarding their advancements in liver therapy, the current landscape of clinical trials, and future visions.
Madrigal encourages interested parties to participate through web access for all presentations, marking an inclusive approach to communication with investors.
Investor and Media Contacts
For further inquiries, investors can reach out to Tina Ventura via email at IR@madrigalpharma.com. Media inquiries can be directed to Christopher Frates at media@madrigalpharma.com. Both contacts invite open channels for dialogue, aiming to keep stakeholders well-informed about Madrigal's ongoing initiatives.
Frequently Asked Questions
What is Madrigal Pharmaceuticals focused on?
Madrigal Pharmaceuticals specializes in the development of innovative therapies for liver diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH).
What is Rezdiffra?
Rezdiffra is an oral medication approved for treating MASH, targeting key aspects of the liver disease known for having high unmet medical needs.
Where can I access the webcasts from the conferences?
The webcasts will be available on Madrigal’s Investor Relations Events page, offering live access to presentations.
How can I contact Madrigal Pharmaceuticals?
Investors can reach out via email at IR@madrigalpharma.com, while media inquiries should be sent to media@madrigalpharma.com.
When are the conferences taking place?
The conferences are scheduled for November and December, featuring various presentations that showcase Madrigal's cutting-edge research and developments.
